JCO Exclusive: Predicting Response to Anti-HER2 Treatments: Is HER2 the Only Biomarker?
27 Oct 2014 6:58 PM
By Shira Klapper, Senior Writer/Editor
For the past 15 years, anti-HER2 treatments have been used to treat women with HER2-positive breast cancer. In all that time, the HER2 biomarker has remained the sole biomarker used to predict whether patients will be sensitive to anti-HER2 treatments, which are comprised of monoclonal antibodies that work by binding to HER2 and inducing the cell’s death.
Now, a new study published in the Journal of Clinical Oncology (JCO), published online, ahead of print, October 13, asks—are there additional biomarkers, independent of HER2, that can help to identify who might benefit from anti-HER2 monoclonal antibodies, specifically the combination of pertuzumab plus trastuzumab?